Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands.
Department of Surgery, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
Curr Oncol Rep. 2022 Jun;24(6):793-808. doi: 10.1007/s11912-022-01248-6. Epub 2022 Mar 17.
Based on good local control rates and an excellent safety profile, guidelines consider thermal ablation the gold standard to eliminate small unresectable colorectal liver metastases (CRLM). However, efficacy decreases exponentially with increasing tumour size. The preferred treatment for intermediate-size unresectable CRLM remains uncertain. This systematic review and meta-analysis compare safety and efficacy of local ablative treatments for unresectable intermediate-size CRLM (3-5 cm).
We systematically searched for publications reporting treatment outcomes of unresectable intermediate-size CRLM treated with thermal ablation, irreversible electroporation (IRE) or stereotactic ablative body-radiotherapy (SABR). No comparative studies or randomized trials were found. Literature to assess effectiveness was limited and there was substantial heterogeneity in outcomes and study populations. Per-patient local control ranged 22-90% for all techniques; 22-89% (8 series) for thermal ablation, 44% (1 series) for IRE, and 67-90% (1 series) for SABR depending on radiation dose. Focal ablative therapy is safe and can induce long-term disease control, even for intermediate-size CRLM. Although SABR and tumuor-bracketing techniques such as IRE are suggested to be less susceptible to size, evidence to support any claims of superiority of one technique over the other is unsubstantiated by the available evidence. Future prospective comparative studies should address local-tumour-progression-free-survival, local control rate, overall survival, adverse events, and quality-of-life.
鉴于良好的局部控制率和出色的安全性,指南将热消融视为消除不可切除的结直肠肝转移瘤(CRLM)的金标准。然而,疗效随肿瘤大小的增加呈指数级下降。对于中等大小的不可切除 CRLM,首选治疗方法仍不确定。本系统回顾和荟萃分析比较了不可切除的中等大小 CRLM(3-5cm)的局部消融治疗的安全性和疗效。
我们系统地搜索了报告不可切除的中等大小 CRLM 采用热消融、不可逆电穿孔(IRE)或立体定向消融体放射治疗(SABR)治疗的结果的出版物。没有发现比较研究或随机试验。评估疗效的文献有限,且研究人群和结局存在较大异质性。所有技术的患者局部控制率为 22-90%;热消融为 22-89%(8 个系列),IRE 为 44%(1 个系列),SABR 为 67-90%(1 个系列),取决于放射剂量。局部消融治疗安全且可诱导长期疾病控制,即使对于中等大小的 CRLM 也是如此。尽管 SABR 和肿瘤包围技术(如 IRE)被认为对肿瘤大小不敏感,但现有证据无法支持任何一种技术优于另一种技术的说法。未来的前瞻性比较研究应关注局部肿瘤无进展生存率、局部控制率、总生存率、不良事件和生活质量。